First Atlas Detailing In Vivo Reflectance Confocal Microscopy Published

ROCHESTER, NY – The In Vivo Reflectance Confocal Microscopy technology helps healthcare practitioners both improve their clinical judgments and assist in monitoring treatment. The first comprehensive atlas detailing the technology is now published.
By: Lucid, Inc
 
 
Spread the Word
Listed Under

Tags:
Lucid
Skin Cancer
In Vivo Reflectance Confocal Microscopy
Rcm Technology

Industrys:
Medical
Technology

Feb. 25, 2008 - PRLog -- ROCHESTER, NEW YORK, USA –  As skin cancer cases continue to rise, the worldwide deployment of In Vivo Reflectance Confocal Microscopy (RCM) (Confocal Imaging) technology – which produces digital images of a patient’s skin with cellular detail similar to that obtained from histology of surgical biopsies – can help healthcare practitioners both speed and improve their clinical judgments and assist in monitoring treatment.  In support of RCM technology, the world’s first available comprehensive atlas detailing the technology has been published.

"Reflectance Confocal Microscopy of Cutaneous Tumors: An Atlas with Clinical, Dermoscopic and Histological Correlations" (Salvador González, Melissa Gill, and Allan C. Halpern, Editors; Informa Healthcare, Publisher), is a comprehensive, full-color atlas detailing the potential of RCM technology and its possible applications for clinical practitioners.  The hard-cover first edition atlas totals 280-pages.

Specifically, In Vivo Reflectance Confocal Microscopy allows optical sectioning of an area of skin without physical sectioning, assisting dermatologists to examine detailed features of a skin lesion without taking a biopsy specimen.  RCM technology can also assist dermatopathologists to determine the best location for a section and dermatological surgeons to determine the margins of a lesion to be excised.

The contents of "Reflectance Confocal Microscopy of Cutaneous Tumors" are:
   I. BASIC PRINCIPLES
   II. NORMAL SKIN
   III. KERATINOCYTIC TUMORS (Seborrheic keratoses, Clear cell acanthoma, Porokeratosis, Squamous neoplasia, Basal cell carcinoma)
   IV. MELANOCYTIC TUMORS (Lentigo, Congenital and common acquired   melanocytic nevi, Dysplastic nevi, Malignant melanoma, Blue nevus, Spitz nevus)
   V. OTHER TUMORS (Trichoepithelioma, Sebaceous hyperplasia, Dermatofibroma, Angioma, Mycosis fungoides)
   VI. CLINICAL APPLICATIONS (Adjunct to clinical diagnosis, RCM-guided biopsy site selection, RCM-assisted assessment of treatment response, RCM-assisted in-vivo margin mapping, RCM-Assisted ex-vivo margin assessment)
   VII. FUTURE PERSPECTIVES

The editors of the atlas are three of the world’s leading RCM medical researchers: Salvador González, M.D., Ph.D., Faculty, Dermatology, MSKCC, New York, NY, Assistant Prof, Dermatology, HMS, Boston, Mass., USA;   Melissa Gill, M.D., Dermatopathologist, Quest Diagnostics Inc., Teterboro, New Jersey, USA (formerly with MSKCC, New York, NY); and Allan C. Halpern, Chief, Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY USA.

"Reflectance Confocal Microscopy of Cutaneous Tumors" (ISBN: 9780415451048) is available immediately from Informa Healthcare (http://catalogue.informahealthcare.com) at http://catalogue.informahealthcare.com/pjbp/products/1000....

Lucid Inc. an RCM Leader
The leader in the development and worldwide deployment of RCM technology is Lucid, Inc. (www.lucid-tech.com) of Rochester, New York, USA.  Lucid is the creator of the VivaScope® reflective confocal microscopy imaging microscope and of the VivaNet®, a network-based, DICOM-compliant medical information system that enables the transfer of VivaScope® digital images between practitioners and pathologists for rapid review of confocal images.

Atlas author Dr. González is among several European diagnostic readers providing confocal imaging services for European dermatology patients using Lucid’s VivaScope® Confocal Imagers.  The readers are also beginning validation testing of Lucid’s VivaNet® telemedicine information system of transferring and managing clinical data between the private practitioners and the diagnostic readers.

For information on Lucid’s VivaScope® or VivaNet® technology, contact Lucid on the web at http://www.lucid-tech.com, by email at info@lucid-tech.com, or by phone at +1-585-239-9800.

Download high resolution photos:  www.lucid-tech.com/news/photos-images.asp

Press contacts:  Don Goncalves, 781-793-9380, dgoncalves@tizinc.com; or Brandie Gerrish, 781-793-9380, bgerrish@tizinc.com

# # #

Lucid, Inc., based in Rochester, New York (USA) is a medical device and information company with offices in North America, Europe, and Australia.  Lucid is dedicated to providing improved care for dermatology patients by coupling its noninvasive VivaScope® cellular imaging technology with its innovative VivaNet® medical information system to allow secure, HIPAA compliant, near real-time collaboration between dermatologists and other medical specialists.  The VivaNet® system provides rapid online medical image transfer, storage, and retrieval thus enabling these critical collaborative consultations.  The technologies delivered by Lucid provide images that physicians use in forming critical clinical judgments in cases of dermatologic disease, while ensuring patient comfort and piece of mind.

VivaNet® and VivaScope® are registered trademarks of Lucid, Inc.
End



Like PRLog?
9K2K1K
Click to Share